Where Is the Ventrogluteal Muscle? Its Location and Uses

The ventrogluteal area sits on the side of your hip, over the thick belly of the gluteus medius and gluteus minimus muscles. It is not a single discrete muscle but rather a region defined by the overlap of those two muscles on the lateral aspect of the pelvis, roughly where your hand naturally falls if you press your palm against the bony prominence at the top of your thigh bone. The site was first championed in the 1950s as a safer target for intramuscular injections, and it remains the recommended injection site in most current nursing literature, yet it is still underused in everyday clinical practice for reasons that have more to do with habit than anatomy.

The Muscles That Make Up the Ventrogluteal Area

When clinicians refer to the “ventrogluteal muscle,” they are really talking about two muscles stacked on top of each other. The gluteus medius is the more superficial one, a broad, fan-shaped muscle that covers much of the outer surface of the pelvis. Beneath it lies the gluteus minimus, a smaller muscle with a similar shape. Together they create a substantial pad of muscle tissue on the side of the hip. Ultrasound studies confirm that at the ventrogluteal injection site the gluteus minimus sits directly under the gluteus medius, and the combined muscle thickness from the surface fascia down to bone is what clinicians measure when choosing needle length.¹

These muscles are not just padding. The gluteus medius stabilizes the pelvis during the first phase of every step you take, preventing your hip from dropping on the opposite side. It also helps initiate pelvic rotation while walking. The gluteus minimus takes over as a primary hip stabilizer during the middle and late phases of your stride.² Together, they keep you upright and balanced during virtually every weight-bearing activity. Interestingly, the thickness of these muscles does not correlate well with hip-abductor strength or functional performance in healthy adults, so a thicker muscle pad does not necessarily mean a stronger hip.³

Where Exactly Is It on Your Body

The ventrogluteal site is not on the buttock where most people picture a “glute injection.” It is on the side of the hip, forward (ventral) of the classic buttock area (the dorsogluteal site). You can think of it as the fleshy zone between the bony knob at the top of your thigh bone, known as the greater trochanter, and the front rim of your pelvis. The area lies well away from the sciatic nerve, the superior gluteal artery’s main trunk, and the large fat deposits that sit over the traditional buttock.

Healthcare providers use two main landmark methods to pinpoint the exact injection spot. The more widely taught one is often called the V method. You place the heel of your opposite hand on the greater trochanter, point your index finger toward the bony prominence at the front of the hip, and spread your middle finger backward to form a V shape. The injection goes into the center of that V.⁴ The second approach, known as the geometric or G method, uses fixed anatomical landmarks and measurements rather than finger-spans to mark the site on the skin. Both methods have been validated against ultrasound imaging.⁵

The G method appears to be more reliable. In one comparative study, the G method produced successful intramuscular needle placement about three-quarters of the time, compared with just under 60% for the V method. The difference was especially pronounced in women: the G method succeeded in roughly 59% of female participants while the V method performed even worse, and in both methods women faced a higher risk of either hitting bone or landing in subcutaneous fat.⁶ For men, the G method succeeded in over 90% of attempts. These numbers underscore that site identification is not foolproof and that factors like body composition matter a great deal.

Why This Site Is Preferred for Intramuscular Injections

The ventrogluteal site’s biggest selling point is safety. The traditional dorsogluteal injection, the one most people picture when they think “shot in the butt,” goes into the upper-outer quadrant of the buttock. That area sits uncomfortably close to the sciatic nerve. In cadaver measurements, the average distance from the dorsogluteal injection point to the sciatic nerve was about 9 centimeters. By contrast, the ventrogluteal site averaged roughly 18 centimeters away from the same nerve, effectively doubling the safety margin.⁷ Sciatic nerve injury from a misplaced gluteal injection can cause pain, numbness, and even foot drop, so that extra distance is clinically meaningful.

Beyond nerve safety, the ventrogluteal area has a thinner layer of subcutaneous fat compared with the dorsogluteal site. A cross-sectional study found that subcutaneous fat, muscle, and total tissue were all significantly thicker at the dorsogluteal site than at the ventrogluteal site, and fat was significantly thicker in women than men at both locations.⁸ Thinner fat means a standard-length needle is more likely to actually reach the muscle, which is the whole point of an intramuscular injection. When medication ends up in the fat layer instead of muscle, absorption slows and the drug may not work as intended. Reviewers have also noted that the dorsogluteal site’s thick fatty tissue commonly causes problems and that medication absorbs more slowly there.⁹

The ventrogluteal region also has relatively few large blood vessels. While some branches of the superior gluteal artery or vein may be present, the site is far less vascular than the dorsogluteal region. A cadaver study measured the mean distance from the ventrogluteal injection point to the superior gluteal artery at roughly 14 millimeters and to the superior gluteal nerve at about 12 millimeters, though these distances varied considerably across specimens.¹⁰ That variability is a reminder that no injection site is completely risk-free, but on balance, the ventrogluteal area comes with fewer hazards.

Less Pain, Less Bruising

Patients generally report less discomfort with ventrogluteal injections than with dorsogluteal ones. A systematic review and meta-analysis pooling data from nine studies found that pain scores were meaningfully lower at the ventrogluteal site. The same analysis found significantly less bleeding and less hematoma formation at 48 and 72 hours after injection when the ventrogluteal site was used.¹¹ These are real quality-of-life differences for patients receiving frequent injections, such as those on long-acting antipsychotic medications or testosterone therapy.

Body position during the injection also matters. A crossover study in women compared ventrogluteal injections given while standing versus lying down. Participants reported significantly less pain in the standing position, with average pain scores on a visual scale of about 1.1 when standing compared with roughly 1.9 when lying down.¹² The likely explanation is that standing shifts body weight onto the opposite leg and naturally relaxes the gluteal muscles on the injection side, making the needle encounter less resistance. This is a simple intervention that could make injections more comfortable, though most clinical guidelines still describe the procedure with the patient lying on their side.

How Body Size and Sex Affect Injection Success

A meta-analysis of tissue-thickness data found that at the ventrogluteal site the combined muscle thickness averages roughly 36 to 38 millimeters, while the subcutaneous fat layer averages about 20 millimeters, depending on the landmark method used.¹³ Those are population averages, though, and individual variation is wide. Sex and body mass index are the two biggest predictors of whether a given needle length will land in muscle or miss.

Women tend to carry more subcutaneous fat over the gluteal region than men, so the same needle may reach muscle easily in a man but stop short in a woman of the same weight. One study found that needle-length selection is particularly critical for women with a BMI under about 23 and a weight under 60 kilograms, where the risk shifts toward hitting bone because the fat and muscle layers are thinner. At the other end, women with a BMI over 30 and a hip circumference above 90 centimeters face the opposite problem: a standard needle may not be long enough to clear the fat.⁶ Deep gluteal injections in larger or obese patients, especially women, often require longer needles to reach the muscle mass.¹⁴

For obese individuals, there is a wrinkle in the ventrogluteal-versus-dorsogluteal comparison. A cadaver study found that in obese specimens, the injected material ended up in the subcutaneous layer rather than the muscle at the ventrogluteal site, while the dorsogluteal site actually had a higher success rate in those same obese cadavers.¹⁵ This does not overturn the general preference for the ventrogluteal site, but it does suggest that clinicians caring for obese patients should think carefully about needle length and may need to reassess site choice on a case-by-case basis. The issue is not that the ventrogluteal site is unsafe in larger patients; it is that a standard-length needle simply may not be long enough to cross the subcutaneous layer there.

The Ventrogluteal Site in Children

Most pediatric vaccination guidelines point nurses to the anterolateral thigh for infants and young toddlers, but research suggests the ventrogluteal area is a viable alternative even in very young children. A study of 642 children aged 2 to 18 months developed age-specific templates for identifying the ventrogluteal site and then used ultrasound to compare tissue composition at that site versus the thigh. The ventrogluteal area was clearly identifiable by the template and deemed suitable for intramuscular injection in those infants.¹⁶

A separate study looked more closely at children under three and found that the muscle at the ventrogluteal site is adequately developed even in infants between 1 and 12 months of age. In children aged 12 to 36 months the ventrogluteal muscle was even thicker than the anterolateral thigh muscle.¹⁷ For toddlers who need multiple vaccinations at a single visit, having the ventrogluteal site as an additional option reduces the number of injections crowded into one small thigh.

Why Nurses Still Reach for the Buttock

Despite decades of evidence favoring the ventrogluteal site, most nurses around the world still default to the dorsogluteal. Surveys paint a consistent picture. One study of Turkish nurses found that only about 17% reported using the ventrogluteal site frequently, while roughly 36% said they avoided it simply because they were not accustomed to it. Their knowledge scores on ventrogluteal anatomy and technique were limited, averaging about 14 correct answers out of 24 questions.¹⁸

Another study found that about a third of nurses frequently used the dorsogluteal site and that the main barriers to switching were a lack of knowledge about how to find the ventrogluteal landmarks and a worry about causing harm. After a focused training session, knowledge scores jumped dramatically, suggesting the resistance is rooted more in educational gaps than in any genuine shortcoming of the site itself.¹⁹ The irony is sharp: nurses avoid the safer site out of concern about harming patients, while continuing to use the site that actually carries higher risks of nerve injury, poor absorption, and pain.

Part of the problem is institutional momentum. Nursing programs in many countries historically taught the dorsogluteal site as the standard, and clinical mentors pass on what they know. Switching injection habits in a hospital or clinic requires not just individual retraining but updated policy, new procedure videos, and hands-on practice sessions with anatomical models. Some facilities have made the switch successfully, but the process is slow and uneven.

Practical Uses Beyond Routine Injections

The ventrogluteal site is not limited to vaccines. It is widely used for administering long-acting injectable medications in psychiatry. Many antipsychotic medications come in depot formulations designed to be injected into a large muscle and released slowly over weeks. Because patients on these medications receive repeated injections at regular intervals, the comfort and safety advantages of the ventrogluteal site compound over time. Research has noted that obesity is highly prevalent among individuals with severe mental illness, making appropriate needle-length selection at the ventrogluteal site especially important for this population.²⁰

Hormone therapy is another common application. Testosterone cypionate and estradiol valerate, both oil-based injectable hormones, require deep intramuscular delivery for proper absorption. The ventrogluteal site’s thick muscle and relatively thin fat layer make it a natural fit. Some patients who self-administer these hormones at home find the side-of-the-hip location easier to reach than the thigh, though others find the opposite. Personal preference, hand dominance, and comfort with the landmark technique all play a role in which site works best for self-injection.

Antibiotics, anti-emetics, and certain analgesics given intramuscularly also land at the ventrogluteal site when the volume of medication is moderate, typically up to about 3 to 4 milliliters in an adult. Larger volumes than that can cause pain and tissue distension regardless of where the injection goes. For medications that are known to be irritating to tissue, the Z-track technique, where the skin is pulled to the side before insertion so the needle path does not create a straight channel back to the surface, is often combined with ventrogluteal injection to reduce leakage and discomfort.

How the Site Was First Proposed

The ventrogluteal injection site is not a modern invention. It was proposed in 1954 by the Swiss anatomist Von Hochstetter, specifically to avoid the sciatic nerve injuries that plagued dorsogluteal injections. In the decades since, studies have confirmed Hochstetter’s reasoning, demonstrating the site’s greater distance from the sciatic nerve, its relatively sparse vasculature aside from some branches of the superior gluteal vessels, and its thinner subcutaneous fat compared with the dorsogluteal area.¹¹ The fact that it took seven decades for clinical practice to begin catching up with the anatomical evidence is a familiar story in healthcare: changing a well-ingrained procedural habit is far harder than producing the research that justifies the change.

The ultrasonographic studies that now support the ventrogluteal site were not available in Hochstetter’s era. His original recommendation rested on cadaver dissections and anatomical reasoning. Modern imaging has not only confirmed his conclusions but refined them, allowing researchers to measure tissue layers to the millimeter across hundreds of participants of varying body types. Those measurements have made it possible to develop algorithms that match needle length to a patient’s BMI and hip circumference, moving the field toward genuinely individualized injection technique rather than the one-size-fits-all approach that dominated for most of the twentieth century.

What the Ventrogluteal Site Does Not Solve

No injection site eliminates all risk. Even at the ventrogluteal site, poor technique can lead to complications. Using a needle that is too long in a very thin person can strike the iliac bone, while using one that is too short in a larger person can deposit medication in fat. Infection risk, though low, exists any time a needle breaks the skin. And some patients simply find injections at this site psychologically uncomfortable because it feels unfamiliar: most people expect a shot in the arm or the buttock, and the side of the hip can seem strange.

The ventrogluteal site also cannot accommodate every medication volume. Very large-volume injections, anything much beyond 4 milliliters, are generally better split across two sites or given by a different route entirely. And for some clinical scenarios, like emergency epinephrine in the thigh or rapid IV-push medications, the ventrogluteal site is simply not relevant. It occupies a specific niche: planned intramuscular injections of moderate volume in a clinical or home setting where the provider has time to identify the landmarks properly.